Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Assets (2016 - 2025)

AC Immune (ACIU) has disclosed Assets for 10 consecutive years, with $193.0 million as the latest value for Q4 2025.

  • Quarterly Assets fell 26.78% to $193.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $193.0 million through Dec 2025, down 26.78% year-over-year, with the annual reading at $193.0 million for FY2025, 26.78% down from the prior year.
  • Assets for Q4 2025 was $193.0 million at AC Immune, down from $263.6 million in the prior quarter.
  • The five-year high for Assets was $283.5 million in Q4 2021, with the low at $193.0 million in Q4 2025.
  • Average Assets over 5 years is $227.8 million, with a median of $206.1 million recorded in 2023.
  • The sharpest move saw Assets plummeted 31.93% in 2022, then increased 27.9% in 2024.
  • Over 5 years, Assets stood at $283.5 million in 2021, then tumbled by 31.93% to $193.0 million in 2022, then rose by 6.78% to $206.1 million in 2023, then grew by 27.9% to $263.6 million in 2024, then decreased by 26.78% to $193.0 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $193.0 million, $263.6 million, and $206.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.